S1 Dataset - حسب Riham Saud Alhazmy (19697677)

"…</p><p>Results</p><p>The mean HbA1c level decreased from 8.61 ± 1.70 to 7.92 ± 1.60 after implementing the WhatsApp group instructions; the values showed a significant difference (t-value = 5.107 and <i>P</i>-value < 0.001). …"

Particepant recruitment flowchart. حسب Riham Saud Alhazmy (19697677)

"…</p><p>Results</p><p>The mean HbA1c level decreased from 8.61 ± 1.70 to 7.92 ± 1.60 after implementing the WhatsApp group instructions; the values showed a significant difference (t-value = 5.107 and <i>P</i>-value < 0.001). …"

Motor function impairment in the three stroke models. حسب Oliver Schmitt (159300)

"…Different from the sMCAO, the dMCAO and ICH had no significant change in the temporal parameter of stride length, The paw intensity and max area of affected limbs of ICH rats had a similar significant decrease with sMCAO. …"

Footprints of Pr77^Gag on the WT structure model. حسب Suresha G. Prabhu (19797666)

"…All nucleotides that show a reactivity decrease >40% upon Gag addition, also show statistically significant difference according to the Mann–Whitney non parametrical U test (<i>p</i> < 0.05). …"

Dataset. حسب Megan Null (4621039)

"…When adjusted for age and sex, improvement in the UVA risk group over 6 hours was associated with a non-statistically significant 43% decrease in odds of mortality (aOR 0.57, 95%CI 0.29–1.07, p = 0.08). …"

Stop codon readthrough for tRNA modification gene deletion mutants. حسب Léo Hardy (22538036)

Comparison of DSIMC generating co-cultures in the second week of incubation on days 9, 12 and 14. حسب Nils Ågren (21474419)

Tryptamine Metabolism and Functionalization in Gut Commensal Bacteria Expand Human Tryptamine Signaling Responses حسب Hyun Bong Park (1576939)

"…Interestingly, <b>1</b> also exhibits significant inhibitory activity against inflammatory soluble epoxide hydrolase with a half-maximal inhibitory concentration of 420 nM. …"

Footprints of Pr77^Gag on the WT and LRI-III mutant packaging signal RNAs. حسب Suresha G. Prabhu (19797666)

"…All nucleotides that show a reactivity decrease >40% upon Gag addition, also show statistically significant difference according to the Mann–Whitney non parametrical U test (<i>p</i> < 0.05). …"

Probe IDs for protein EpiScore. حسب Atchara Dawangpa (16560735)

"…A total of 41 participants were assessed at baseline, 7 weeks, and 14 weeks into the training. …"

Flow chart of study design. حسب Atchara Dawangpa (16560735)

"…A total of 41 participants were assessed at baseline, 7 weeks, and 14 weeks into the training. …"

Critical Role of Transcription Factor CtSR in Mediating Ergosterol Biosynthesis and DMI Fungicides Sensitivity in Colletotrichum truncatum حسب Wei Sun (93580)

"…Deletion of <i>CtSR</i> rendered a naturally resistant isolate highly sensitive to DMIs, significantly reduced total ergosterol levels, decreased <i>CYP51s</i> expression compared to the wild type, and abolished DMI-induced expression of <i>CYP51s</i>. …"

Critical Role of Transcription Factor CtSR in Mediating Ergosterol Biosynthesis and DMI Fungicides Sensitivity in Colletotrichum truncatum حسب Wei Sun (93580)

"…Deletion of <i>CtSR</i> rendered a naturally resistant isolate highly sensitive to DMIs, significantly reduced total ergosterol levels, decreased <i>CYP51s</i> expression compared to the wild type, and abolished DMI-induced expression of <i>CYP51s</i>. …"

Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"

Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... حسب Chao Song (379006)

"…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …"